Valinor Discovery Raises $13 Million Seed to Scale AI-Powered Platform for Smarter Clinical Trials
Valinor Discovery, a San Francisco-based biotechnology company applying machine learning to rethink drug development and increase clinical trial success rates, has secured $13 million in seed funding in a round aimed at scaling its proprietary multimodal machine learning platform for predicting patient response and derisking therapeutic R&D. The financing reflects growing investor interest in companies that use advanced analytics and real patient data to improve the notoriously high failure rates in clinical trials, which remain one of the most costly and uncertain aspects of bringing new medicines to market.
The seed round was led by CRV, one of Silicon Valley’s long-established venture capital firms known for backing early-stage technology and life sciences ventures, alongside Harpoon Ventures, a firm that supports founders building pioneering technologies across software and biotech. Additional lead investors included Amino Collective and Pelion Venture Partners, each contributing to the company’s ability to deepen its datasets, recruit top machine learning talent, and expand operations as it advances its platform. Numerous angel investors also participated in the round, bringing domain expertise and operational experience to strengthen Valinor’s early growth.
Founded by CEO and co-founder Joshua Pacini, Valinor Discovery is building machine learning models that integrate patient-derived multi-omics data with clinical outcomes to create predictive insights into how individuals respond to therapies before clinical trials begin. Unlike traditional bioinformatics approaches that focus on isolated data types, Valinor’s platform trains on richly matched datasets combining genomic, proteomic, and clinical endpoints. By modeling patient response holistically, drug developers can better distinguish likely responders from non-responders, refine clinical trial design, and uncover novel biological signals that might inform new indications or optimizations in therapeutic approaches.
The company’s approach is grounded in real patient data, with models trained on longitudinal multi-omic and clinical outcome sets that help anticipate transcriptomic shifts, protein abundance changes, and other biomarkers of response — all before a single patient is enrolled in a costly trial. Valinor’s technology aims to help pharmaceutical and biotech partners reduce trial failures, cut R&D costs, and accelerate the delivery of lifesaving treatments by making early development decisions more data-driven and less uncertain.
Valinor’s funding milestone comes as the industry seeks new ways to address persistent challenges in drug development. Despite massive investments in novel therapeutics, overall clinical trial success rates remain low, with many programs failing due to lack of efficacy or unforeseen safety issues. Valinor’s machine learning models are designed to surface meaningful features of patient response that might otherwise remain hidden in traditional analyses, offering a more nuanced view of how candidate treatments perform against complex biological backdrops. This capability has attracted attention from investors who see predictive analytics as a transformative force in therapeutic discovery and development.
The participation of CRV, Harpoon Ventures, Amino Collective, and Pelion Venture Partners highlights broad confidence in Valinor’s vision and the potential impact of its technology. CRV’s involvement signals belief in the platform’s ability to reshape early-stage drug development workflows, while Harpoon’s support reflects enthusiasm for companies integrating computational innovation with life sciences. Amino Collective and Pelion Venture Partners bring additional biotech and computational expertise to Valinor’s ecosystem, positioning the company to leverage cross-disciplinary insights and accelerate momentum.
In practical terms, the new capital will fund expansion of Valinor’s proprietary datasets, which are central to training increasingly sophisticated models, and bolster hiring of machine learning experts and scientific staff to enhance the platform’s capabilities. The company’s San Francisco-based team is expected to grow as demand for predictive models — capable of identifying likely responders early and guiding smarter trial design — increases across pharmaceutical programs in oncology and other therapeutic areas.
Valinor’s work bridges advanced computational techniques and real clinical data, creating tools that aim to provide drug developers with early signals that better reflect human biology and reduce dependence on costly trial-and-error approaches. By empowering partners with actionable insights into patient response, the company seeks to help shorten development timelines and increase the chances of clinical success — ultimately benefiting patients who rely on new therapies reaching the market faster and more efficiently.
The $13 million seed funding round represents a major step in Valinor Discovery’s journey to transform how therapeutic R&D is conducted. With investor backing aligned behind its multimodal machine learning platform, the company is poised to expand its influence in the biotech ecosystem and contribute to the next generation of data-driven drug development solutions.
